Synaffix B.V., a biotechnology company based in Amsterdam, Netherlands, and Qurient Co., Ltd., a clinical-stage biopharmaceutical company headquartered in Seongnam-Si, South Korea, have entered into a licensing agreement to develop a dual-payload antibody-drug conjugate (ADC) targeting solid tumors. https://www.coherentmarketinsights.com/news/synaffix-and-qurient-entered-into-a-licensing-agreement-to-develop-a-dual-payload-antibody-drug-conjugate-1591